Follicular Lymphoma  >>  oxaliplatin  >>  Phase 2
Welcome,         Profile    Billing    Logout  

16 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxaliplatin / Generic mfg.
ACTRN12623000620628: NHL38 Epco-Sandwich: A trial to assess the safety and efficacy of Epcoritamab-containing combination salvage therapy followed by autologous stem cell transplantation and Epcoritamab consolidation in patients with relapsed large B-cell lymphoma.

Not yet recruiting
2
39
 
Australasian Leukaemia and Lymphoma Group (ALLG), Australasian Leukaemia and Lymphoma Group (ALLG)
Diffuse Large B-Cell Lymphoma
 
 
NCT00006473: Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed
2
72
US
oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP
National Cancer Institute (NCI)
Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Waldenström Macroglobulinemia
02/06
 
NCT01538641: Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas

Completed
2
43
US
Rituximab, Gemcitabine, Oxaliplatin
Auxilio Mutuo Cancer Center
Refractory Aggressive Non-Hodgkin's Lymphoma, Relapsing Aggressive Non-Hodgkin's Lymphoma
08/07
12/08
NCT01307592: Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma

Checkmark P3 data - ASCO
Jun 2012 - Jun 2012: P3 data - ASCO
Unknown status
2
70
US
rituximab, gemcitabine hydrochloride, lenalidomide, oxaliplatin
Auxilio Mutuo Cancer Center
Lymphoma
02/13
 
2006-003243-23: A Phase II Study of OXALIPLATIN and GEMCITABINE in Combination with IFOSFAMIDE plus RITUXIMAB (R-GIFOX) as 2nd-line Chemotherapy in Relapsed and Primary Refractory Lymphoma

Ongoing
2
45
Europe
GEMZAR*INFUS 1FL 1G POLV, GEMZAR*1FL 200MG POLV, ELOXATIN*IV 1FL POLV 50MG, MABTHERA*EV 1FL 50ML 500MG, HOLOXAN*IV 1FL 1G+FL 50ML SOLV, MABTHERA*EV 2F 10ML 100MG, ELOXATIN*IV 1FL POLV 100MG, GEMZAR*INFUS 1FL 1G POLV, GEMZAR*1FL 200MG POLV, ELOXATIN*IV 1FL POLV 50MG, MABTHERA*EV 1FL 50ML 500MG, HOLOXAN*IV 1FL 1G+FL 50ML SOLV, MABTHERA*EV 2F 10ML 100MG, ELOXATIN*IV 1FL POLV 100MG
ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE \"G. PASCALE\"
Patients with Relapsed and Primary Refractory Lymphoma
 
 
2010-018866-21: Intensified program including Bendamustine followed by PBSC mobilization and high dose therapy and autograft for patients with relapsed or resistant CD 20+ Follicular Non Hodgkin Lymphoma: a multicenter, pivotal GITIL study

Ongoing
2
20
Europe
Bendamustine Hydrochloride, ELOXATIN*IV FL POLV 100MG, Bendamustine Hydrochloride, ELOXATIN*IV FL POLV 100MG
A.I.L. (ASSOCIAZIONE ITALIANA CONTRO LE LEUCEMIE, LINFOMI E MIELOMI
RESISTANT FOLLICULAR NON HODGKIN LYNPHOMA
 
 
NCT02624492 / 2014-004794-16: To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL

Completed
2
21
Europe
BI 836826, GemOx, Rituximab
Boehringer Ingelheim
Lymphoma, Large B-Cell, Diffuse
03/18
03/18
2019-002373-59: A phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients aggressive Lymphoma. Eine Phase-II-Studie zur Untersuchung von Gemcitabin/Oxaliplatin/Rituximab mit Tafasitamab (MOR-00208) bei Patienten mit aggressivem Lymphom.

Ongoing
2
64
Europe
Tafasitamab, MOR00208, Lyophilisate for solution for infusion, MINJUVI® 200 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
University Medical Center of the Johannes Gutenberg University Mainz, Incyte Corporation
Malignant B-cell lymphoma Aggressives B-Zell Lymphom, Malignant Lymphoma Aggressives Lymphom, Diseases [C] - Cancer [C04]
 
 
PTLD-2, NCT02042391 / 2013-004479-11: Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy

Completed
2
60
Europe
Rituximab sc, Mabthera sc, Rituximab sc consolidation, Rituximab sc combined with CHOP chemotherapy, Cyclophosphamide, Adriamycine, Vincristin, Prednisone, Rituximab sc combined with alternating chemotherapy with CHOP and DHAOx, Oxaliplatin, Cytarabine, Ara-C, Dexamthasone
Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH
Posttransplant Lymphoproliferative Disorder
07/21
07/22
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
12/24
07/27
NCT06287398: Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL

Not yet recruiting
2
39
NA
Epcoritamab
Australasian Leukaemia and Lymphoma Group
DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, DLBCL, Nos Genetic Subtypes, High Grade B-Cell Lymphoma, Not Otherwise Specified, Follicular Large Cell Lymphoma, Relapsed, Follicular Large Cell Lymphoma
11/26
11/31
NCT00954005: Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma

Terminated
1/2
56
Europe
Therapy with Rituximab, Gemcitabine and Oxaliplatin, Rituximab = Mabthera, Rituxan, Gemcitabine = Gemzar, Oxaliplatin = Eloxatin
German Low Grade Lymphoma Study Group
Indolent Lymphoma
06/11
06/12
ZUMA-1, NCT02348216 / 2015-005007-86: Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Checkmark Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Dec 2022 - Dec 2022: Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Feb 2021 - Feb 2021: Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASH 2020
More
Completed
1/2
307
Europe, Canada, US, RoW
Axicabtagene Ciloleucel, Yescarta®, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone
Kite, A Gilead Company
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
07/23
07/23
NCT02953509 / 2016-003408-29: Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Checkmark Data from P1b trial in combination with rituximab for DLBCL at ASH 2022
Jan 2023 - Jan 2023: Data from P1b trial in combination with rituximab for DLBCL at ASH 2022
Hourglass Apr 2020 - Sep 2020 : Safety and efficacy data from P1b trial in combination with rituximab for DLBCL
Checkmark In combination with rituximab in DLBCL and FL patents at EHA 2019 [screenshot]
Jun 2019 - Jun 2019: In combination with rituximab in DLBCL and FL patents at EHA 2019 [screenshot]
More
Terminated
1/2
178
Europe, US, RoW
Magrolimab, Hu5F9-G4, Rituximab, RITUXAN®, MabThera, Gemcitabine, Gemzar®, Oxaliplatin, Eloxatin®
Gilead Sciences, The Leukemia and Lymphoma Society
Non Hodgkin Lymphoma
03/24
03/24
EPCORE NHL-3, NCT04542824: Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL

Active, not recruiting
1/2
102
Japan
epcoritamab (monotherapy), GEN3013, DuoBody®-CD3xCD20, EPKINLY™, epcoritamab, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, R-CHOP, gemcitabine and oxaliplatin, Gemox, epcoritamab (maintenance), rituximab and lenalidomide, R2
Genmab, AbbVie
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
12/24
12/24
EPCORE NHL-2, NCT04663347 / 2020-000845-15: Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

Checkmark Data from arm 6 of EPCORE NHL-2 trial for r/r/ follicular lymphoma at ASH 2022
Dec 2022 - Dec 2022: Data from arm 6 of EPCORE NHL-2 trial for r/r/ follicular lymphoma at ASH 2022
Checkmark Data from arm 2b of EPCORE NHL-2 trial for r/r follicular lymphoma at ASH 2022
Dec 2022 - Dec 2022: Data from arm 2b of EPCORE NHL-2 trial for r/r follicular lymphoma at ASH 2022
Checkmark Data from arm-4 of EPCORE NHL-2 trial for r/r DLBCL at ASH 2022
More
Recruiting
1/2
662
Europe, US, RoW
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, R-CHOP, rituximab and lenalidomide, R2, rituximab and bendamustine, BR, rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin, R-DHAX/C, gemcitabine and oxaliplatin, GemOx, Epcoritamab, GEN3013, DuoBody®-CD3xCD20, EPKINLY™, rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone, R mini-CHOP, Lenalidomide, rituximab, ifosfamide, carboplatin, and etoposide phosphate, R-ICE
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
03/29
03/29

Download Options